- Home
- FBIO vs CTSO Comparison
FBIO vs CTSO Comparison
Compare FBIO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- CTSO
- Stock Information
- Founded
- FBIO 2006
- CTSO 1997
- Country
- FBIO United States
- CTSO United States
- Employees
- FBIO N/A
- CTSO N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- FBIO Health Care
- CTSO Health Care
- Exchange
- FBIO Nasdaq
- CTSO Nasdaq
- Market Cap
- FBIO 53.5M
- CTSO 57.6M
- IPO Year
- FBIO N/A
- CTSO N/A
- Fundamental
- Price
- FBIO $2.12
- CTSO $1.16
- Analyst Decision
- FBIO Strong Buy
- CTSO Buy
- Analyst Count
- FBIO 2
- CTSO 2
- Target Price
- FBIO $21.00
- CTSO $5.50
- AVG Volume (30 Days)
- FBIO 204.0K
- CTSO 324.9K
- Earning Date
- FBIO 08-14-2025
- CTSO 08-07-2025
- Dividend Yield
- FBIO N/A
- CTSO N/A
- EPS Growth
- FBIO N/A
- CTSO N/A
- EPS
- FBIO N/A
- CTSO N/A
- Revenue
- FBIO $59,301,000.00
- CTSO $36,107,520.00
- Revenue This Year
- FBIO $51.59
- CTSO $11.15
- Revenue Next Year
- FBIO $44.74
- CTSO $21.39
- P/E Ratio
- FBIO N/A
- CTSO N/A
- Revenue Growth
- FBIO N/A
- CTSO 20.18
- 52 Week Low
- FBIO $1.33
- CTSO $0.71
- 52 Week High
- FBIO $2.36
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- FBIO 63.67
- CTSO 60.19
- Support Level
- FBIO $1.90
- CTSO $1.03
- Resistance Level
- FBIO $2.04
- CTSO $1.22
- Average True Range (ATR)
- FBIO 0.10
- CTSO 0.09
- MACD
- FBIO 0.02
- CTSO 0.03
- Stochastic Oscillator
- FBIO 81.40
- CTSO 86.61
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.